Che-Leung Law

Che-Leung Law has extensive work experience in the biotechnology and pharmaceutical industries. Che-Leung is currently serving as the Chief Scientific Officer at Abacus Bioscience Inc since February 2022. Prior to this, they held various positions at Harpoon Therapeutics, including SVP of Translational Medicine from January 2020 to December 2021, and VP of Translational Medicine from April 2017 to January 2020.

Before joining Harpoon Therapeutics, Law worked at Seattle Genetics as a Senior Director of Preclinical Research from March 2014 to April 2017. Prior to this, they served as the Director of Preclinical Research, Director of Molecular Oncology & Immunology, and Associate Director of Molecular Oncology & Immunology at Seattle Genetics from 2000 to 2014. Che-Leung also held the position of Senior Principal Scientist from September 2000 to February 2004.

Law's career began at Xcyte Therapies, where they worked as a Scientist from March 1997 to August 2000. Additionally, they held a role as an Affiliate Assistant Professor at the University of Washington from April 1997 to January 2010.

Overall, Law has demonstrated expertise in scientific leadership and research in the biotechnology industry, with a focus on translational medicine, preclinical research, and molecular oncology & immunology.

Che-Leung Law holds a Ph.D. in Pathobiology from the University of Minnesota. Prior to that, they obtained an M.Phil. in Biochemistry and a B.Sc. in Biochemistry & Zoology from The University of Hong Kong.